These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31911716)

  • 21. Market Exclusivity and Changes in Competition and Prices Associated With the US Food and Drug Administration Unapproved Drug Initiative.
    Gunter SJ; Kesselheim AS; Rome BN
    JAMA Intern Med; 2021 Aug; 181(8):1124-1126. PubMed ID: 33999110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How insurers' bargaining power affects drug prices in Medicare Part D.
    Natl Bur Econ Res Bull Aging Health; 2009; (4):1-2. PubMed ID: 20355274
    [No Abstract]   [Full Text] [Related]  

  • 23. [Medications: dear and expensive?].
    Rojahn J
    Klin Monbl Augenheilkd; 2014 Feb; 231(2):108-13. PubMed ID: 25298981
    [No Abstract]   [Full Text] [Related]  

  • 24. [Development costs, regulation and audit in the German SHI Drug Sector].
    Kamp F; Walter P; Bücheler R
    Gesundheitswesen; 2014 Jan; 76(1):7-18. PubMed ID: 24446140
    [No Abstract]   [Full Text] [Related]  

  • 25. Precompetitive research: a new prescription for drug development?
    Woodcock J
    Clin Pharmacol Ther; 2010 May; 87(5):521-3. PubMed ID: 20407454
    [No Abstract]   [Full Text] [Related]  

  • 26. Sending pharma better signals.
    Avorn J
    Science; 2005 Jul; 309(5735):669. PubMed ID: 16051753
    [No Abstract]   [Full Text] [Related]  

  • 27. The economics of parallel trade.
    Danzon PM
    Pharmacoeconomics; 1998 Mar; 13(3):293-304. PubMed ID: 10178655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Indication-specific Drug Pricing - Simple in Theory, Complex in Reality.
    Kwon S
    Manag Care; 2018 May; 27(5):23-25. PubMed ID: 29763404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmaceuticals and medical devices: cost savings. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-33. PubMed ID: 23297446
    [No Abstract]   [Full Text] [Related]  

  • 30. [The course of the drug, clinical research and commercialization. Constraints, obstacles, delays and costs].
    Giri I; Rouillon F
    Encephale; 2006 Oct; 32(5 Pt 3):S858-60. PubMed ID: 17119487
    [No Abstract]   [Full Text] [Related]  

  • 31. Using a drug-safety tool to prevent competition.
    Sarpatwari A; Avorn J; Kesselheim AS
    N Engl J Med; 2014 Apr; 370(16):1476-8. PubMed ID: 24738666
    [No Abstract]   [Full Text] [Related]  

  • 32. Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices.
    Lexchin J
    CMAJ; 2006 Apr; 174(8):1120-1. PubMed ID: 16606961
    [No Abstract]   [Full Text] [Related]  

  • 33. The art of the alliance.
    Menzel GE; Xanthopoulos KG
    Nat Biotechnol; 2012 Apr; 30(4):313-5. PubMed ID: 22491275
    [No Abstract]   [Full Text] [Related]  

  • 34. Who's really raising drug prices?
    Zagorin A
    Time; 1999 Mar; 153(9):46-8. PubMed ID: 10346086
    [No Abstract]   [Full Text] [Related]  

  • 35. Determinants of Market Exclusivity for Prescription Drugs in the United States.
    Kesselheim AS; Sinha MS; Avorn J
    JAMA Intern Med; 2017 Nov; 177(11):1658-1664. PubMed ID: 28892528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
    Gitter DM
    Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
    [No Abstract]   [Full Text] [Related]  

  • 37. Trajectories of Injectable Cancer Drug Costs After Launch in the United States.
    Gordon N; Stemmer SM; Greenberg D; Goldstein DA
    J Clin Oncol; 2018 Feb; 36(4):319-325. PubMed ID: 29016226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The ongoing regulation of generic drugs.
    Frank RG
    N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
    [No Abstract]   [Full Text] [Related]  

  • 39. Patent nonsense: evidence tells of an industry out of social control.
    Mintzberg H
    CMAJ; 2006 Aug; 175(4):374. PubMed ID: 16908900
    [No Abstract]   [Full Text] [Related]  

  • 40. Improving the PPI sample for prescription pharmaceuticals.
    Kelly GG
    Mon Labor Rev; 1997 Oct; 120(10):10-7. PubMed ID: 10176326
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.